dc.contributor.author | Kahraman, Seda | |
dc.contributor.author | Erul, Enes | |
dc.contributor.author | Seyyar, Mustafa | |
dc.contributor.author | Gumusay, Ozge | |
dc.contributor.author | Bayram, Ertugrul | |
dc.contributor.author | Okutur, Sadi Kerem | |
dc.date.accessioned | 2023-05-29T12:09:11Z | |
dc.date.available | 2023-05-29T12:09:11Z | |
dc.date.issued | 2023 | en_US |
dc.identifier.citation | Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A. (2023). Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer. Future Oncology, (0). | en_US |
dc.identifier.issn | 1479-6694 | |
dc.identifier.uri | https://doi.org/10.2217/fon-2022-1287 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12294/3874 | |
dc.description.abstract | Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | FUTURE MEDICINE LTD | en_US |
dc.relation.ispartof | FUTURE ONCOLOGY | en_US |
dc.identifier.doi | 10.2217/fon-2022-1287 | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | CDK 4 | en_US |
dc.subject | 6 Inhibitors | en_US |
dc.subject | HER2-Negative Metastatic Breast Cancer | en_US |
dc.subject | HR-Positive | en_US |
dc.subject | Letrozole | en_US |
dc.title | Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer | en_US |
dc.type | article | en_US |
dc.department | Tıp Fakültesi, Dahili Tıp Bölümü | en_US |
dc.authorid | 0000-0002-8079-7739 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.institutionauthor | Okutur, Sadi Kerem | |
dc.authorwosid | FRE-1156-2022 | en_US |
dc.identifier.wos | WOS:000991646700001 | en_US |